Based on the Panacea Biotec Limited stock forecast from 0 analysts, the average analyst target price for Panacea Biotec Limited is not available over the next 12 months. Panacea Biotec Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Panacea Biotec Limited is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Panacea Biotec Limited’s stock price was INR 141.95. Panacea Biotec Limited’s stock price has changed by +2.20% over the past week, +6.49% over the past month and +18.74% over the last year.
No recent analyst target price found for Panacea Biotec Limited
No recent average analyst rating found for Panacea Biotec Limited
Company Overview Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine. It also exports its products to approximately 36 countries, including the United States, Germany, Russian Federation, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Philippines, Sri Lanka, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. The company was incorporated in 1984 and is based in New Delhi, India. Read Less
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription...Read More
Frequently Asked Questions About Panacea Biotec Limited (PANACEABIO:NSE) Stock
Stock Target Advisor's fundamental analysis for Panacea Biotec Limited's stock is Neutral.
Unfortunately we do not have enough data on PANACEABIO:NSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PANACEABIO:NSE's stock to indicate what its average analyst target is.
PANACEABIO:NSE stock's Price/Earning ratio is 28.61.
Our analysis grades PANACEABIO:NSE stock's Price / Earning ratio at D-. This means that PANACEABIO:NSE stock's Price/Earning ratio is above 40% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this PANACEABIO:NSE may be fairly valued for its sector
The last closing price of PANACEABIO:NSE's stock was INR 141.95.
The most recent market capitalization for PANACEABIO:NSE is INR 7.45B.
Unfortunately we do not have enough analyst data on PANACEABIO:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Panacea Biotec Limited's stock.
As per our most recent records Panacea Biotec Limited has 1,794 Employees.
Panacea Biotec Limited's registered address is B-1 Extension/G-3, New Delhi, India, 110044.
You can get more information about it from Panacea Biotec Limited's website at https://www.panaceabiotec.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PANACEABIO:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
